HENLIUS (02696) announced that the U.S. Food and Drug Administration (FDA) has recently approved the Investigational New Drug (IND) application for a Phase 1 clinical trial of the company's self-developed ipilimumab biosimilar HLX13 (Recombinant Anti-CTLA-4 Fully Human Monoclonal Antibody Injection) as first-line treatment for patients with unresectable hepatocellular carcinoma (HCC). The company plans to initiate this international multi-center clinical trial in the United States once conditions are met.